<DOC>
	<DOC>NCT01407523</DOC>
	<brief_summary>To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.</brief_summary>
	<brief_title>An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subject is a male or female aged ≥ 16 years Subject has Partial Onset Seizures that are classifiable according to the 1981 International League Against Epilepsy (ILAE) classification of Epileptic Seizures Subject weighs ≥ 40 kg Subject is currently taking Levetiracetam (LEV) as an adjunctive antiepileptic oral treatment with 1 to 3 other Antiepileptic Drugs (AEDs) Subject has problems with venous accessibility Subject has participated in another clinical/pharmacological study during the last 4 weeks prior to the Screening Visit Subject is pregnant or lactating Subject has a history of suicide attempt(s) or presents with current depressive signs, current suicidal ideation, and/or behavior Subject has clinically significant Electrocardiogram (ECG) abnormalities according to the investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Infusion</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
</DOC>